Abstract
Strengthening the detection of second-line drug-resistance is a key tuberculosis (TB) control priority. The performance of MTBDRplus, a multidrug-resistant (MDR)-TB assay is reduced when suboptimal ramp rates are used. We investigated ramp rate’s effect on MTBDRsl; the most widely-used molecular second-line drug-resistant TB assay.
We tested 52 smear-negative Xpert MTB/RIF Ultra-positive sputa and a Mycobacterium tuberculosis (Mtb) dilution series at manufacturer-recommended (2.2°C/s) or most common suboptimal ramp rate (4.0°C/s; identified via an earlier survey). Mtb-complex DNA (TUB-band)-positivity, indeterminate rates, fluoroquinolone- and second-line injectable-resistance accuracy, banding differences and, separately, inter-reader variability were assessed.
39% of re-surveyed laboratories (5/13) did not use the manufacturer-recommended MTBDRsl ramp rate. On sputum, this ramp rate improved indeterminates vs. 4.0°C/s (0/52 vs. 7/51; p=0.006), false drug-resistance calls (0/104 vs. 6/102; p=0.013), and incorrect banding calls (0/1300 vs. 55/1275; p<0.001). Valid results (neither TUB-negative, indeterminate, nor any false drug-resistance calls) (52/52 vs. 41/51; p=0.001) on sputa hence improved by +21% (95% CI: 8-34%) with optimal ramp rate usage. Suboptimal ramp rate increased banding call inter-reader variability [52/1300 (4%) vs. 34/1300 (3%); p=0.030] on sputa but not dilution series; highlighting the importance of using clinical specimens for assay performance evaluations.
Suboptimal ramp rate contributes to poor MTBDRsl performance. Ramp rate correction will improve second-line drug-resistant TB diagnoses. Laboratories must ensure the optimal manufacturer-recommended ramp rate is used.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the EDCTP2 program supported by the European Union (grant SF1401, OPTIMAL DIAGNOSIS), The Center for Innovation in Point-of-Care Technologies for HIV/AIDS at Northwestern University (National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health, Award Number U54EB027049), and the National Institute of Allergy and Infectious Diseases. Research reported in this publication was also supported by the South African Medical Research Council. The content is the solely the responsibility of the authors and does not necessarily represent the official views of the South African Medical Research Council. Hain Lifesciences donated the MTBDRsl kits used for the dilution series. They did not have any role in study design or result interpretation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Health Research Ethics Committee of Stellenbosch University (N16/04/045) and Western Cape Research Ethics Committee (WC_2016RP18_637). All methods were in accordance with relevant guidelines and regulations. Permission was granted to access anonymised residual specimens collected as part of routine diagnostic practices and thus patient informed consent was waived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Foundation for Innovative New Diagnostics, Geneva, Switzerland
Funding This work is supported by the EDCTP2 program supported by the European Union (grant SF1401, OPTIMAL DIAGNOSIS), The Center for Innovation in Point-of-Care Technologies for HIV/AIDS at Northwestern University (National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health, Award Number U54EB027049), and the National Institute of Allergy and Infectious Diseases.
Research reported in this publication was also supported by the South African Medical Research Council. The content is the solely the responsibility of the authors and does not necessarily represent the official views of the South African Medical Research Council.
Hain Lifesciences donated the MTBDRsl kits used for the dilution series. They did not have any role in study design or result interpretation.
Data Availability
Available from the corresponding author.
